Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer (JBCRG-C05)

Trial Profile

Cohort study evaluating efficacy of bevacizumab plus paclitaxel in patients with HER2-negative inoperable or metastatic breast cancer (JBCRG-C05)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms B-SHARE
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 04 Nov 2016 Planned End Date changed from 31 Oct 2017 to 30 Apr 2017.
    • 01 Oct 2014 Status changed from recruiting to active, no longer recruiting according to results presented at the Official 10th European Breast Cancer Conference.
    • 01 Nov 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top